


SUPPLEMENTAL MATERIAL

Herz et al., <http://www.jem.org/cgi/content/full/jem.20142047/DC1>

Video 1. Antiviral T cell interactions with CD11c⁺ microglia after adoptive immunotherapy. The representative time lapses show virus-specific CD8⁺ (P14) and CD4⁺ (SMARTA) interacting with CD11c-YFP⁺ microglia in the persistently infected brain parenchyma 12 d after adoptive immunotherapy. Note that CD8⁺ T cell forms a stable interaction with the CD11c⁺ cell, whereas the CD4⁺ T cell remains in motion while interacting with its target. Interactions are highlighted with white circles. This video is shown at 15 frames/s.

Table S1. Q-PCR primer sequences used in this study

Gene name	Primer sequence	GenBank accession no.	Amplicon T_m
			°C
<i>β-actin</i>	F: 5'-AGTCATTGTAGAAGGTGTGG-3' R: 5'-GTGGGAATGGTCAGAAGG-3'	NM_007393	#
<i>Cd11c</i>	F: 5'-CTGGATAGCCTTTCTCTGCTG-3' R: 5'-GCACACTGTGTCCGAACTC-3'	NM_021334	60.4
<i>Ccl2</i>	F: 5'-GTCCTGTCTGCTTCTG-3' R: 5'-GCTCTCCAGCCTACATTCATTG-3'	NM_011333	62.0
<i>Ccl3</i>	F: 5'-GATTCCACGCCAATTCATCG-3' R: 5'-TTCAGTTCAGGTCAGTGATG-3'	NM_011337	62.0
<i>Ccl4</i>	F: 5'-AAACCTAACCCCGACCAAC-3' R: 5'-CGGGAGGTGTAAGAGAAACA-3'	NM_013652	60.4
<i>Ccl5</i>	F: 5'-GGGTACCATGAAGATCTCTGC-3' R: 5'-TCTAGGGAGAGGTAGGCAAAG-3'	NM_013653	58.0
<i>Ccl7</i>	F: 5'-GAAAACCCCAACTCCAAAGC-3' R: 5'-CCTTAGGACCGTGATCAACAC-3'	NM_013654	60.4
<i>Cxcl1</i>	F: 5'-AACCGAAGTCATAGCCACAC-3' R: 5'-CAGACGGTGCCATCAGAG-3'	NM_008176	57.9
<i>Cxcl2</i>	F: 5'-GAAGTCATAGCCACTCTCAAGG-3' R: 5'-CTTCCGTTGAGGGACAGC-3'	NM_009140	57.0
<i>Cxcl9</i>	F: 5'-AGTCCGCTGTTCTTTTCCTC-3' R: 5'-TGAGGTCTTTGAGGGATTTGTAG-3'	NM_008599	60.4
<i>Cxcl10</i>	F: 5'-TCAGCACCATGAACCAA-3' R: 5'-CTATGGCCCTCATTCTCACTG-3'	NM_021274	60.4

This supplemental table provides the forward and reverse primer sequences used to quantify expression of the denoted chemoattractants. β -Actin served as a housekeeping control gene. T_m , melting temperature; #, reference gene.

Table S2, included in a separate Excel file, shows differential gene expression in CD11c⁺ microglia after immunotherapy.